Decisions made today about research, prevention, and innovation will shape the health and wellbeing of future generations.
EAP was therefore pleased to be represented at an important meeting at the European Parliament, dedicated to strengthening the place of paediatric research and child health within future EU health and research policy.
Prof. Berthold Koletzko, Prof. Ann de Guchtenaere, Dr Iren Kantor, and Dr Nora Karara joined the discussion on behalf of EAP, bringing the voice and experience of Europe’s paediatric community to the table. Their contribution highlighted a central message: investing in children’s health is one of the most effective ways to promote lifelong health, prevent disease, and support a healthier future for Europe.
The meeting provided an important opportunity to underline the need for stronger European support for paediatric research, greater recognition of prevention in childhood and adolescence, and a clearer commitment to ensuring that children benefit from future medical advances and innovation.
In parallel, EAP and partner societies are preparing a position paper setting out key recommendations to promote child health, innovation, and prevention within EU research policy. The paper will be published in due course, and EAP looks forward to sharing it with its members, partner societies, and wider network once available.
This initiative reflects EAP’s ongoing commitment to ensuring that children and adolescents are not left at the margins of health policy, but recognised as central to Europe’s future health, resilience, and prosperity.
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.
